U.S. Food and Drug Administration Approves Vemlidy® (tenofovir
https://www.gilead.com/news-and-press/press-room/press-releases/2022/11/us-food-and-drug-administration-approves-vemlidy-tenofovir-alafenamide-for-treatment-of-chronic-hepatitis-b-virus-infection-in-pediatric-patients
WebNov 2, 2022 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy ® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B …
DA: 17 PA: 85 MOZ Rank: 89